Anti-cancer regimen using anti-CD47 and anti-CD20 antibodies

摘要

A regimen for treating CD20+ cancer, particularly lymphoma, is disclosed. This regimen involves several cycles of administration of anti-CD20 and anti-CD47 antibodies at appropriate doses and dosing intervals.